Abiraterone trial to launch in early stage prostate cancer
A highly anticipated new androgen synthesis inhibitor, abiraterone acetate, will be the subject of the first clinical study in men with localized, but high-risk, prostate cancer
High-throughput RNAi screening in cultured cells has opened up new routes to studying gene function, identifying drug targets, and understanding pathways, including those most relevant to cancer biology
DF/HCC offers a multitude of funding opportunities to its members to encourage and enhance the collaborative spirit of research within the Harvard medical community
DF/HCC members receive Harvard Catalyst Pilot Grants
The Harvard Clinical and Translational Science Center is a university-wide collaborative effort committed to reducing the burden of human illness by helping researchers better leverage the human and technological resources of Harvard and its Academic Healthcare Centers
